924-P: Glycemic Outcomes Improved and Maintained Regardless of Demographic Characteristics of Young Children with Type 1 Diabetes Using Closed-Loop System
Authors: EKHLASPOUR LAYA , REED ZACHARIAH , BUCKINGHAM BRUCE A. , DEBOER MARK D. , FORLENZA GREGORY P. , KINGMAN RYAN S. , SCHOELWER MELISSA , WADWA R. PAUL , LUM JOHN W. , KOLLMAN CRAIG , BECK ROY , BRETON MARC D. 
Published: June 2023

Automated insulin delivery improves glycemic control in young children with type 1 diabetes (T1D). We investigated the potential impact of baseline participant characteristics on glycemic improvements when using the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ). After a 13 wk randomized, multi-center, controlled trial comparing CIQ (CLC) to standard care insulin delivery plus CGM (SC) in 102 children with T1D age 2 to &lt;6 years, 95 continued CLC for 13 wks (CLC-CLC, N=62) or transitioned to CLC (SC-CLC, N=33). We compared glycemic outcomes from the RCT to the extension phase in subgroups based on baseline characteristics. At baseline, participants were 3.9 ± 1.2 years old with 25% minority race/ethnicity; 48% household income &lt;$100,000; 57% parents with bachelor’s degree or less; 21% public insurance; 69% baseline HbA1c ≥7%; and 34% used multiple daily injections. In the SC-CLC group, time 70-180 mg/dL (TIR) improved in all subgroups regardless of race/ethnicity, family income, education, health insurance type, baseline HbA1c, and experience with devices (Table 1). In the CLC-CLC group, TIR improvement with CLC during the RCT was maintained regardless of subgroup. Our results support the findings that young children with T1D benefit from using CIQ regardless of their baseline characteristics. The benefit is maintained over a 26-week period.

Disclosure
L.Ekhlaspour: Consultant; Ypsomed AG, Tandem Diabetes Care, Inc., Other Relationship; NIH - National Institutes of Health, Research Support; MannKind Corporation, Tandem Diabetes Care, Inc., JDRF, Speaker's Bureau; Insulet Corporation. C.Kollman: Research Support; Insulet Corporation, Dexcom, Inc., Tandem Diabetes Care, Inc. R.Beck: Consultant; Eli Lilly and Company, Novo Nordisk, Diasome, Insulet Corporation, Research Support; Tandem Diabetes Care, Inc., Beta Bionics, Inc., Dexcom, Inc., Bigfoot Biomedical, Inc., Medtronic, Ascensia Diabetes Care, Roche Diabetes Care, Eli Lilly and Company, Novo Nordisk. M.D.Breton: Consultant; Dexcom, Inc., Tandem Diabetes Care, Inc., Roche Diabetes Care, Sanofi, Arecor, Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc., Novo Nordisk. Pedap trial study group: n/a. Z.Reed: None. B.A.Buckingham: Advisory Panel; Medtronic, Novo Nordisk, Consultant; Lilly, Research Support; Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc. M.D.Deboer: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc. G.P.Forlenza: Advisory Panel; Medtronic, Consultant; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Lilly Diabetes, Research Support; Medtronic, Abbott, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc. R.S.Kingman: None. M.Schoelwer: Research Support; Tandem Diabetes Care, Inc., Insulet Corporation. R.Wadwa: Consultant; Eli Lilly and Company, Other Relationship; Dexcom, Inc., Eli Lilly and Company, Research Support; Dexcom, Inc., Eli Lilly and Company, Beta Bionics, Inc., Tandem Diabetes Care, Inc. J.W.Lum: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK127551); Tandem Diabetes Care, Inc; Dexcom, Inc.